Balanced news tone
News Sentiment
BLCO sentiment intelligence
Bausch + Lomb Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
83/100 classification confidence.
directly relevant articles
high-authority source matches
-5.4% over one week, +7.6% over four weeks, trend inactive, and near fair-value range.
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 Others
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 11:30
- Source
- GlobeNewswire
BLCO Stock Drops After-Hours — Bausch + Lomb Halts Glaucoma Eye Drop Program After Trial Failure
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jul 2026 16:31
- Source
- Stocktwits
Why Bausch + Lomb (BLCO) Stock Is Trading Lower Today
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 10 Jul 2026 21:27
- Source
- Market source
Price to sales forward of Bausch + Lomb Corporation – NYSE:BLCO
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 08:52
- Source
- TradingView
Bausch + Lomb (BLCO) Could Be 57% Below Fair Value After Product Updates
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 06:11
- Source
- Market source
Bausch + Lomb Says Phase 2 Trial for Glaucoma Neuroprotective Candidate Fails to Meet Primary Endpoint
- Tone
- Negative 31/100
- Event
- Market update
- Published
- 09 Jul 2026 20:57
- Source
- MT Newswires
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 09 Jul 2026 20:30
- Source
- Business Wire
Bausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient Care
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 11:00
- Source
- Business Wire
Bausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jul 2026 11:15
- Source
- Business Wire
Bausch + Lomb sets July 29 call for Q2 2026 results
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jul 2026 11:15
- Source
- Stock Titan
Dry eye treatment tied to lower anxiety, better confidence in Bausch + Lomb survey
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Stock Titan
Bausch + Lomb Corp updates investors on strategic focus, shares trade on NYSE
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 15:48
- Source
- Ad-hoc-news.de
Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Blink Triple Care Preservative Free U.S. Launch
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jun 2026 07:00
- Source
- simplywall.st
Bausch & Lomb (NYSE: BLCO) grants 15,842 RSUs to director
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- Stock Titan
Medical Devices & Supplies - Specialty Stocks Q1 Teardown: Bausch + Lomb (NYSE:BLCO) Vs The Rest
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 May 2026 07:00
- Source
- Market source
Bausch + Lomb (BLCO) Starts 2026 With Ongoing Losses That Test Bullish Margin Narratives
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Apr 2026 07:00
- Source
- simplywall.st
Bausch + Lomb (BLCO) Surpasses Q1 Earnings and Revenue Estimates
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Apr 2026 07:00
- Source
- Market source
Bausch + Lomb (NYSE:BLCO) Posts Better-Than-Expected Sales In Q1 CY2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- StockStory
Is It Time To Reconsider Bausch + Lomb (BLCO) After Its 28% One-Year Rally?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Apr 2026 07:00
- Source
- Market source
Why Bausch + Lomb (BLCO) Just Strengthened Something Beyond Earnings
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 21 Apr 2026 07:00
- Source
- Market source
Bausch + Lomb brings full-range vision lens implant to Europe
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Apr 2026 07:00
- Source
- Stock Titan
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & Supplies - Specialty Stocks
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Apr 2026 07:00
- Source
- Market source
A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- Market source
Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Mar 2026 07:00
- Source
- Market source
Inside Bausch + Lomb’s glaucoma webinar on new treatments
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Mar 2026 11:18
- Source
- Stock Titan
Assessing Bausch + Lomb (NYSE:BLCO) Valuation After Latest Revenue And Net Loss Update
- Tone
- Negative 34/100
- Event
- Earnings
- Published
- 08 Mar 2026 08:00
- Source
- Market source
Bausch + Lomb (BLCO) Reports Record Q4 2025 Financial Results Driven by Strong Pharmaceutical and Vision Care Growth
- Tone
- Positive 95/100
- Event
- Earnings
- Published
- 27 Feb 2026 08:00
- Source
- Finviz
Bausch + Lomb Q4 Earnings Review: Still A Buy, With Some Caveats (NYSE:BLCO)
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 19 Feb 2026 08:00
- Source
- Seeking Alpha
Bausch & Lomb Earnings: Nice Results from Growth Momentum, Solid Execution, and Pipeline Investment
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 18 Feb 2026 08:00
- Source
- Morningstar
Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Oct 2025 07:00
- Source
- Market source